This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Anyone a member of advfn, would they please paste the above news on there, might stop some 'get rich quick merchants' from selling way way too early.

Cheers GF.

Back to top for Hustler.
cheers GF.

Goldfinger if you wish to read the articles written by M Walters then subscribe to his site. At 75 per annum, it is well worth the fee. Excellent site.

Had a feeling it was going to be a good day, but what a start.

Hang onto to ... something (including your shares!!!).

Ruthenium is making a strong ground for MMG. It will be a foundation for newer generation chemotherapy

gf:

Could you post the Killik
morning report for me today as I'm out most of the day.
cheers.

Will do Mitzy, but lets not forget the news coming from the mike Walters site last night.

Mike Walters as gone ballistic over on his board tonight about MMG, Ive never seen him so brimming with passion. Heres the headlines, two articles in one evening unheard of.................................


A World-Beater?
22/3/2005

Medical Marketing is involved in a remarkable breakthrough.
[Read more]

AND

Do Not Sell MMG
22/3/2005

Dramatic news from Medical Marketing.

TALK OF A 10 BAGGER WITHIN A YEAR.

cheers GF.

Buyers pilling back in after a bit of early profit taking. They must be mad selling.

cheers GF.

Yeah, goldfinger, Ijust think they are mad selling because MMG certainly has a huge future with its ruthenium compounds. I am working in the chemo industry and I know that. MMG will shoot to 350p easily by May.

I hope they do H98. Price still on the rise.

cheers GF.

bought back in to MMG this morning

Well done HM, I was wondering where everyone was. Was thinking everyone was nursing an hangover after the good news yesterday. Blimey they are now nearlly 18% up and this on a rotten day for the market. NICE.

cheers GF.

I am nursing a hangover and I topped up at 223. This is going to be huge with the potential to help a lot of people. I expect we all know someone whos had the big C.

LOL

MS

Awaiting the Killik morning note. They should have a good write up on this one.

cheers GF.

Well its out but for some reason its not downloading, typical.........


Morning Note - Wednesday, 23 March 2005

Paul Kavanagh's view of the day's news and market events

FED rate rise comes with warning on inflationary pressure bonds and stocks slide

Medical Marketing up strongly on cancer vaccine trial result

William Morrison sees board fall out following profit warning

Bounce potential in Neteller, Sportingbet, Cambrian Mining?


--------------------------------------------------------------------------------

Cheers GF.

Killik Broker note now out makes superb reading..................



MEDICAL MARKETING Cancer vaccines update



The long awaited announcement from Medical Marketing (MMI), the pharmaceutical development company, relating to its cancer vaccine program scored well with share holders yesterday. The share price, already up three times since the 14th January, rose further by the close and in morning trade has soared a further 15%. So why is there all of the excitement?



The trial, which has been underway since 2001, took 25 patients with follicular lymphoma and who had been treated with all known available treatments before being accepted. The average life expectancy of a sufferer is around seven years and of course many of these patients were late stage in the treatment. We understand that of the 25, a majority (thought to be 18) responded positively to the treatment by showing an immunological response to the vaccine.



The trial was funded by cancer charities and the full report will be published by Cancer Research UK and LRF.



The significance of this announcement is that this will be treated as a technological break through in making a vaccine work against cancer. Whilst the early trial looked at a particularly viral strand in lymphoma, other trials including myeloma (cancer of the bone marrow) are on going and early results appear to be going the same way. This is increasingly looking like a platform technology with much broader applications.



So how does this all translate for share holders? Medical Marketing, with a low cost operating model and working closely with the public sector and the universities, has a stated policy of licensing the technology to major pharmaceutical companies at the appropriate stage, normally towards the end of phase 2 when much of the value has been captured. We expect, on the back of this data, that a commercial deal will be in the offing in the near term. Licensing deals normally take the shape of an upfront payment followed by key milestone deals. David Best, as the founder of MMI, spent many years in larger pharmaceutical companies working on these types of transactions and therefore is well experienced in this type of deal.



Sitting behind this transaction is of course Oncosense which I believe could potentially be bigger than Genvax. Oncosense looks at the use of ruthenium as an alternative to platinum in cancer drugs and we believe three of the favored compounds will be going to clinical trials in the near term. Trial length will be short so indeed we could have results by the end of 2005. Earlier in January, the company, whilst believing the potency was considerable compared to platinum, was delighted with the safety performance being comparable to the safest drugs on the cancer market.



By the end of 2005, it is thought that the group could have eight or nine phase two clinical trials running in major disease areas like cancers and HIV. With market deals in this space for licensing running from 100 million (for pre-clinical) to 2 billion for phase three, the potential upside for a small 100 million player like MMI is huge. Despite the rise seen so far this year, the shares, which I own, remain with significant potential for the coming months.



cheers GF.

Extract from the Killick notes...............

So how does this all translate for share holders? Medical Marketing, with a low cost operating model and working closely with the public sector and the universities, has a stated policy of licensing the technology to major pharmaceutical companies at the appropriate stage, normally towards the end of phase 2 when much of the value has been captured. We expect, on the back of this data, that a commercial deal will be in the offing in the near term. Licensing deals normally take the shape of an upfront payment followed by key milestone deals. David Best, as the founder of MMI, spent many years in larger pharmaceutical companies working on these types of transactions and therefore is well experienced in this type of deal. ENDS.

Anyone selling now , well you are missing out on a massive gain, and this is JUST THE BEGINNING.

Added more on the broker note.

cheers GF.

Back to top for the lunch time crowd.

Lunch time crowd now going in and buying. Cheers GF.